Cost‐effectiveness of osimertinib versus placebo in resected EGFR‐mutated non‐small cell lung cancer in China

PURPOSE: We aim to assess whether osimertinib postoperative adjuvant therapy, compared with placebo, is cost‐effective in China. METHODS: We set up the Markov model that contains three health states over a 20‐year period. Data were collected from the ADAURA trial that included transition probabiliti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiwen, Du, Jianting, Xu, Guobing, Chen, Chun, Zheng, Bin, Chen, Jiahe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741963/
https://www.ncbi.nlm.nih.gov/pubmed/35689472
http://dx.doi.org/10.1002/cam4.4798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741963/
https://www.ncbi.nlm.nih.gov/pubmed/35689472
http://dx.doi.org/10.1002/cam4.4798

Ejemplares similares